NASDAQ:SCNX Scienture Q1 2026 Earnings Report $0.38 +0.00 (+0.64%) Closing price 04:00 PM EasternExtended Trading$0.38 0.00 (-0.24%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Scienture EPS ResultsActual EPS-$0.08Consensus EPS -$0.23Beat/MissBeat by +$0.15One Year Ago EPSN/AScienture Revenue ResultsActual Revenue$0.06 millionExpected Revenue$0.40 millionBeat/MissMissed by -$344.68 thousandYoY Revenue GrowthN/AScienture Announcement DetailsQuarterQ1 2026Date5/15/2026TimeAfter Market ClosesConference Call DateFriday, May 15, 2026Conference Call Time8:00AM ETUpcoming EarningsScienture's Q2 2026 earnings is estimated for Monday, August 17, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 11, 2026 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Scienture Earnings HeadlinesSCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial TeamJune 9 at 8:05 AM | globenewswire.comScienture (NASDAQ:SCNX) Trading Down 5.3% - Time to Sell?June 6, 2026 | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX is set to go public as soon as June 11, with OpenAI and Anthropic likely to follow. Whitney Tilson - Harvard MBA, former hedge fund manager, and 30-year Wall Street veteran - calls these the most overhyped, overvalued large-cap stocks ever brought to market. Tilson believes a rare economic event is forming, one he says could reset the financial system in ways most investors aren't prepared for. He's put together a free analysis outlining exactly what he sees and the steps he recommends taking with your money now.June 12 at 1:00 AM | Stansberry Research (Ad)SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041June 2, 2026 | globenewswire.comScienture Holdings Announces CFO Resignation, Names Interim SuccessorMay 29, 2026 | tipranks.comSCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin ExpansionMay 18, 2026 | globenewswire.comSee More Scienture Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scienture? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scienture and other key companies, straight to your email. Email Address About ScientureScienture (NASDAQ:SCNX) engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.View Scienture ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Why Oracle's 10% Drop May Be Telling the Wrong StorySpotify's "North Star" Outlook Was Music to Investors EarsCracker Barrel Surges 23% as Earnings Beat Signals Turnaround ProgressChewy’s Growth Engine Is Stronger Than the Market ThinksCasey’s Is Looking Like a Hot Buy as Growth, Buybacks, and Guidance AlignThe “Duck Stock” Keeps Quietly Making Money for Shareholders Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
